Technology

Breathe Easy! with Caeli Nova’s patented breathing technology ‘Cordillera’

Cordillera can be easily retrofitted into in-service commercial or military passenger fleets with minimal downtime
Caeli Nova received initial Design Organisation approval from EASA in December 2020 after an intensive eight-month process

The new technology will help in reducing fuel and emissions while delivering a number of wider operational benefits for airlines and shorter flight times for passengers.

22 March 2020: Caeli Nova, a new entrant in the aerospace sector is all set to launch Cordillera. It is an innovative enhancement to the passenger emergency oxygen system which will deliver improved safety and overcome the limitations while navigating through high terrain regions. Apart from this it will help in reducing fuel and emissions while delivering a number of wider operational benefits for airlines and shorter flight times for passengers.

Tim Wakeford, CEO at Caeli Nova said, “Current regulations limit airlines’ ability to operate the most direct air routes, such as L888 over the Himalayas. Cordillera, which uses our patented breathing technology, allows an aircraft to safely divert at a higher altitude to a suitable airport following a decompression event. As a result, airlines can operate the most optimal routes. In addition to keeping passengers safe and delivering cost and sustainability benefits, continuing the flight at a higher altitude offers the flight crew a safer operating environment in the demanding post-decompression flight phase.”

Caeli Nova received initial Design Organisation approval from EASA in December 2020 after an intensive eight-month process. Throughout this period, Caeli Nova has also worked closely with the regulator to undertake research and development of its technology. Now with the design authority in place, they can now continue development and installation of its first product, Cordillera, under its own Supplementary Type Certificate (STC). Cordillera has been developed in the UK with an exhaustive research and development programme co-funded by Innovate UK, the UK’s innovation agency.

Wakeford added, “Cordillera has undergone extensive testing with both medical and regulatory supervision. The results are a clear demonstration that Cordillera will provide the safe, innovative resolution of a long-term operational limitation.”

Cordillera can be easily retrofitted into in-service commercial or military passenger fleets with minimal downtime and first installations have been scheduled for the end of 2021.